On this page
- What is Stomach Cancer?
- Types of Stomach Cancer
- Early Warning Signs of Stomach Cancer
- Risk Factors for Stomach Cancer
- How Stomach Cancer is Diagnosed
- Stomach Cancer Staging (AJCC 8th Edition)
- Treatment Options for Stomach Cancer
- Why Adjuvant Chemotherapy Matters After Surgery
- What to Expect: A Day at VICI Healthcare for Stomach Cancer Treatment
- Treatment Costs for Stomach Cancer in India
- How Modern Treatment Differs from Traditional Approaches
- Weighing the Benefits and Challenges of Gastric Cancer Treatment
- Managing Side Effects of Gastric Cancer Treatment
- Frequently Asked Questions
What is Stomach Cancer?
Stomach cancer, also known as gastric cancer, develops in the lining of the stomach. It is one of the most common cancers worldwide and represents a significant health burden in India, where H. pylori infection and dietary factors contribute to higher incidence rates. The disease often develops slowly over years, starting as precancerous changes in the stomach lining before progressing to malignancy. Understanding its progression, risk factors, and treatment options is critical for early detection and improved outcomes.
The majority of stomach cancers are adenocarcinomas (95% of cases), which originate in the mucus-secreting cells of the stomach. Other less common types include signet ring cell carcinoma, gastric lymphoma, and gastrointestinal stromal tumors (GIST). Early detection through endoscopy and H. pylori screening in high-risk populations can identify cancers at earlier, more treatable stages. In India, where screening programs are limited outside major centers, public awareness about warning signs remains essential.
Modern treatment approaches include surgery, chemotherapy, targeted therapies, and immunotherapy, often used in combination. Adjuvant chemotherapy after surgery significantly improves survival, particularly in locally advanced cancers. At VICI Healthcare, we combine evidence-based protocols with comprehensive supportive care, addressing nutritional challenges, symptom management, and quality of life throughout the treatment journey.
Types of Stomach Cancer
Adenocarcinoma (Intestinal Type)
Accounts for 95% of gastric cancers. Develops from the mucus-secreting cells of the stomach lining. Associated with chronic inflammation, H. pylori infection, and intestinal metaplasia. Often occurs in the antrum (lower portion) of the stomach.
Signet Ring Cell Carcinoma
Characterized by mucin-filled cells that appear like signet rings under the microscope. Tends to be more aggressive and often presents at advanced stages. Associated with hereditary diffuse gastric cancer (CDH1 mutations) and worse prognosis.
Mucinous Adenocarcinoma
Produces excessive mucin, giving it a gelatinous appearance. Often more aggressive and presents at advanced stages. Distinct molecular profile and may require tailored treatment approaches.
Gastric Lymphoma
Develops from immune cells in the stomach lining. Most cases are mucosa-associated lymphoid tissue (MALT) lymphomas, often H. pylori-related. Early-stage MALT lymphomas may respond to H. pylori eradication alone.
Gastrointestinal Stromal Tumor (GIST)
Arises from interstitial cells of Cajal (KIT-positive cells). Generally slower growth than adenocarcinoma but can metastasize. Responds well to targeted therapy with imatinib and sunitinib.
Cardia Cancer
Occurs near the junction between the esophagus and stomach. Often presents late due to location. May be associated with Barrett’s esophagus and gastroesophageal reflux disease (GERD).
Fundic Cancer
Develops in the upper portion of the stomach. Accounts for a smaller percentage of cases. Often discovered at advanced stages due to the spacious nature of the fundus allowing tumor growth without early symptoms.
Antral Cancer
Occurs in the lower portion of the stomach. Most common location for gastric cancer. Often associated with H. pylori infection and chronic gastritis. May present with early satiety due to narrowing of the pylorus.
Early Warning Signs of Stomach Cancer
- Persistent indigestion and heartburn Antacids no longer provide relief; symptoms persist for more than 2 weeks despite treatment.
- Difficulty swallowing Sensation of food stuck in the throat or pain when swallowing suggests possible cancer in the cardia or fundus.
- Feeling full quickly (early satiety) Eating small amounts leaves you uncomfortably full; related to tumor reducing stomach capacity.
- Persistent stomach pain or discomfort Dull, aching pain in the upper abdomen lasting weeks; not relieved by antacids or dietary changes.
- Loss of appetite Sudden reluctance to eat, especially meat or fatty foods, combined with weight loss.
- Unexplained weight loss Losing 5 kg or more over weeks without intentional dieting; suggests metabolism is being affected by malignancy.
- Persistent nausea and vomiting Especially vomiting blood or material resembling coffee grounds, indicating upper GI bleeding.
- Vomiting blood (hematemesis) Bright red blood or dark, clotted blood in vomit requires urgent evaluation for gastric cancer.
- Black, tarry stools (melena) Dark appearance indicates digested blood from the stomach, suggesting active internal bleeding.
- Unexplained fatigue and weakness Anemia from chronic internal bleeding causes exhaustion, shortness of breath, or dizziness.
- Abdominal bloating and gas Persistent distension and discomfort, particularly after meals, may indicate partial obstruction.
- Swelling and fluid in the abdomen (ascites) In advanced cases, fluid accumulation causes abdominal distension and discomfort.
Many of these symptoms are common and often benign, but persistence for more than 2–3 weeks warrants endoscopic evaluation. Early diagnosis is the most important predictor of treatment success and survival.
Risk Factors for Stomach Cancer
Understanding your risk factors enables earlier screening and prevention strategies. In India, H. pylori prevalence and dietary factors significantly elevate risk in certain populations.
| Risk Factor | How Much It Raises Risk | Notes for Indian Patients |
|---|---|---|
| H. pylori Infection | High (5–10 times increased risk) | 60–70% of Indian population infected; eradication therapy recommended for all infected individuals, especially those with family history or symptoms. |
| Age | Moderate to High (above age 55) | Incidence rises sharply after age 50; screening protocols should begin at age 40 for high-risk groups. |
| Smoking | Moderate (1.5–3 times increased risk) | Bidi smoking and cigarette use both implicated; smokeless tobacco (gutkha, pan) also increases risk. |
| Heavy Alcohol Consumption | Moderate (2–4 times with chronic use) | Alcohol damages stomach lining and synergizes with H. pylori infection; counseling important in high-consumption regions. |
| Family History of Gastric Cancer | High (up to 3 times increased risk) | Hereditary diffuse gastric cancer (CDH1 mutations) can run in families; genetic counseling and early screening advised. |
| Obesity (BMI > 30) | Moderate (1.3–1.8 times increased risk) | Rising in urban India; weight management and regular physical activity protective. |
| Chronic Atrophic Gastritis | Moderate to High | Often develops from long-standing H. pylori infection; endoscopic surveillance recommended every 2–3 years. |
| Intestinal Metaplasia | Moderate (precancerous change) | Found in 10–20% of H. pylori-infected Indians; endoscopic follow-up essential to monitor progression. |
| Pernicious Anemia (Vitamin B12 Deficiency) | Moderate (2–3 times increased risk) | Autoimmune gastritis reduces acid and B12 absorption; regular B12 monitoring and supplementation recommended. |
| Previous Stomach Surgery | Moderate (2–5 times after 15+ years) | Stump cancer risk increases with time; regular surveillance endoscopy advised decades after gastrectomy. |
| Low Socioeconomic Status and Poor Sanitation | Moderate | Higher H. pylori transmission in areas with poor hygiene; public health measures critical. |
| Dietary Factors: Processed and Salted Foods | Moderate (1.2–1.5 times) | Traditional preserved foods and high-salt diets increase risk; emphasis on fresh fruits and vegetables protective. |
Sources: GLOBOCAN 2020, Indian Council of Medical Research (ICMR) National Cancer Registry Programme, WHO guidelines on H. pylori screening.
How Stomach Cancer is Diagnosed
Early diagnosis significantly improves treatment outcomes and survival rates. Diagnosis typically involves a combination of clinical evaluation and imaging studies, with endoscopic biopsy providing definitive confirmation.
-
1
Doctor takes detailed history of symptoms, duration, weight loss, and risk factors including H. pylori status.
Symptom pattern and risk profile guide urgency of investigation and determine which diagnostic tests to prioritize.
-
2
Flexible tube with camera inserted through mouth to visualize the entire stomach lining; biopsies taken from any suspicious areas.
Only way to definitively diagnose gastric cancer and obtain tissue samples for pathological examination; allows assessment of tumor location and extent.
-
3
High-frequency ultrasound probe passed through endoscope to visualize stomach wall layers and regional lymph nodes.
Accurately determines depth of tumor invasion (T-staging) and evaluates nearby lymph nodes; guides surgical planning and prognosis.
-
4
Cross-sectional imaging to assess tumor size, extent, and presence of distant metastases in liver, lungs, and peritoneum.
Essential for staging to determine if cancer has spread; guides decisions on treatment approach (surgery alone vs. neoadjuvant therapy).
-
5
Tissue samples analyzed under microscope; testing for HER2, MSI/MMR, PD-L1 status performed.
Confirms cancer type and grade; identifies specific mutations guiding targeted therapy selection (HER2+ candidates for trastuzumab).
-
6
Complete blood count, liver and kidney function; CEA and CA 19-9 levels may be checked.
Assesses overall health, baseline organ function, and provides markers to monitor treatment response and recurrence.
-
7
Positron emission tomography combined with CT to detect metabolically active cancer cells.
Helpful in detecting distant metastases not visible on standard CT; particularly valuable in advanced stages.
-
8
Stool antigen test, urea breath test, or serology to identify H. pylori infection status.
H. pylori status influences long-term surveillance plans; eradication may reduce risk of recurrence.
Stomach Cancer Staging (AJCC 8th Edition)
Staging determines the extent of cancer spread and guides treatment recommendations. The TNM (Tumor-Node-Metastasis) system is used with the AJCC classification. Stage strongly influences prognosis and treatment decisions.
-
Stage IA
Small tumor limited to innermost stomach lining (T1) with no lymph node involvement (N0). No distant metastases.
- Survival
- 5-year survival approximately 70–75%
- Treatment
- Endoscopic resection for very small lesions, or partial gastrectomy with D2 lymph node dissection. Adjuvant chemotherapy not routinely needed but may be considered for higher-risk features.
-
Stage IB
Either larger tumor confined to submucosa (T2 N0) or small tumor with 1–2 involved lymph nodes (T1 N1). No distant spread.
- Survival
- 5-year survival approximately 60–65%
- Treatment
- Subtotal or total gastrectomy with D2 lymph node dissection. Adjuvant fluoropyrimidine-based chemotherapy (5-FU or capecitabine) for 6 months recommended.
-
Stage II
Moderate-sized tumor involving muscle layer (T3) with no or few lymph nodes involved, or smaller tumor with 3–6 positive nodes (T1-2 N2-3). No metastases.
- Survival
- 5-year survival approximately 40–50%
- Treatment
- Gastrectomy with D2 dissection. Adjuvant chemotherapy with fluoropyrimidine-based regimens strongly recommended for 6 months. Perioperative chemotherapy may be considered.
-
Stage IIIA
Larger tumor extending through muscle and into subserosal layers (T4a) with 1–2 involved nodes, or T3 with 3–6 nodes. No distant spread.
- Survival
- 5-year survival approximately 25–35%
- Treatment
- Neoadjuvant (preoperative) chemotherapy with FOLFOX or CAPOX for 3 cycles, followed by gastrectomy and D2 dissection, then adjuvant chemotherapy for remaining cycles. Total treatment duration 6 months.
-
IIIB
Very large tumor (T4a or T4b) with multiple involved lymph nodes (N2-3), or any T with 7+ involved nodes. Peritoneal involvement may be present.
- Survival
- 5-year survival approximately 15–25%
- Treatment
- Perioperative chemotherapy (neoadjuvant and adjuvant FOLFOX/CAPOX). For HER2-positive tumors, consider adding trastuzumab or ramucirumab. Palliative approaches if unresectable.
-
Stage IV (Metastatic)
Distant spread to liver, lungs, peritoneum, or distant lymph nodes (M1). Regardless of primary tumor or nodal involvement.
- Survival
- 5-year survival approximately 5–10% (median overall survival 8–14 months with modern therapy)
- Treatment
- Palliative chemotherapy with fluoropyrimidine-based regimens (FOLFOX, CAPOX). Add targeted therapy if HER2+ (trastuzumab) or ramucirumab. Consider immunotherapy (nivolumab) in PD-L1+ tumors. Supportive care and symptom management critical.
Survival rates are median estimates based on international registries and Indian institutional data. Individual prognosis depends on performance status, comorbidities, and molecular profile. Stage remains the strongest predictor of outcome. Molecular profiling (HER2, MSI status) increasingly guides treatment selection.
Treatment Options for Stomach Cancer
Gastrectomy (Surgical Resection)
Surgery is the cornerstone of curative treatment for locally advanced stomach cancer. Gastrectomy involves removing the entire stomach or the affected portion, depending on tumor location. Total gastrectomy (removal of entire stomach) is performed for tumors in the cardia or fundus, while subtotal/distal gastrectomy is appropriate for antral tumors when adequate margins are achievable. The extent of lymph node dissection (D1 vs. D2) significantly influences outcomes; D2 dissection (removal of regional lymph nodes in stations 1-7) is the standard in specialized centers and improves survival by 5-10%.
For very early-stage cancers (T1 N0), endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) may be considered in selected patients, preserving the stomach. However, most patients require surgical gastrectomy with adequate margins and lymph node assessment. In advanced unresectable cancers, palliative bypass procedures may be considered to relieve obstruction and improve quality of life.
- Total gastrectomy with D2 lymphadenectomy (standard for proximal/cardia cancers)
- Distal/subtotal gastrectomy with D2 dissection (standard for antral cancers)
- Endoscopic mucosal resection (EMR) for selected early-stage (T1a) lesions
- Endoscopic submucosal dissection (ESD) for well-differentiated early cancers
- Palliative bypass surgery (gastrojejunostomy) for unresectable tumors with obstruction
Adjuvant Chemotherapy
Adjuvant (post-operative) chemotherapy is recommended for all patients with stage IB disease or higher. Standard regimens are based on fluoropyrimidines combined with platinum agents. The most widely used approach is FOLFOX (fluorouracil, leucovorin, and oxaliplatin) given for 6 months. This combination improves overall survival by approximately 12-15% compared to surgery alone. Capecitabine and oxaliplatin (CAPOX or CAPEOx) is an alternative with similar efficacy and improved tolerability for some patients.
In India, where advanced-stage presentation is common, adjuvant chemotherapy is increasingly recognized as critical for extending survival. Treatment duration is typically 6 months total. Side effects include peripheral neuropathy from oxaliplatin, hand-foot syndrome from fluoropyrimidines, and hematologic toxicities, all manageable with supportive care and dose modifications. For HER2-positive tumors (15-20% of gastric cancers), adding trastuzumab to chemotherapy further improves outcomes.
- FOLFOX: Fluorouracil (5-FU) 400 mg/m² IV bolus + Leucovorin 200 mg/m² + Oxaliplatin 85 mg/m² every 2 weeks × 12 cycles (6 months)
- CAPOX: Capecitabine 1000 mg/m² twice daily × 14 days + Oxaliplatin 130 mg/m² on day 1, every 3 weeks × 8 cycles (6 months)
- Fluorouracil monotherapy with leucovorin (for selected patients unable to tolerate platinum)
- Trastuzumab 6 mg/kg IV every 3 weeks concurrent with chemotherapy (for HER2+ tumors)
Perioperative Chemotherapy (Neoadjuvant + Adjuvant)
Perioperative chemotherapy (neoadjuvant followed by adjuvant) is increasingly used for locally advanced gastric cancer. This approach shrinks the tumor before surgery, improving resectability and achieving better R0 resection (complete tumor removal with negative margins). The neoadjuvant phase typically consists of 3 cycles of FOLFOX or CAPOX delivered before surgery, followed by gastrectomy and D2 dissection, then adjuvant chemotherapy to complete 6-9 months of total treatment.
International trials (MAGIC, FNCLCC) have demonstrated 5-year survival improvements of 10-15% with perioperative chemotherapy compared to surgery alone. In India, this approach is becoming standard for locally advanced disease at tertiary centers. Neoadjuvant chemotherapy also provides advantages in evaluating treatment response (chemotherapy response predicts surgical outcome) and may select out patients with micrometastatic disease who would not benefit from surgery.
- Neoadjuvant FOLFOX: 3 cycles before surgery, then 3 more cycles after surgery
- Neoadjuvant CAPOX: 3 cycles before surgery, then 3 more cycles after surgery
- Ramucirumab (anti-VEGF monoclonal antibody) 8 mg/kg IV every 2 weeks in addition to chemotherapy for advanced tumors
Palliative Chemotherapy for Advanced/Metastatic Disease
For metastatic gastric cancer (stage IV), palliative chemotherapy aims to extend survival, relieve symptoms, and maintain quality of life. The standard first-line approach is a fluoropyrimidine-platinum doublet (FOLFOX or CAPOX). Median overall survival with modern chemotherapy is 8-14 months, compared to 3-4 months with supportive care alone. Response rates are 40-50%, with many patients experiencing symptom improvement and better functional status.
For HER2-positive advanced gastric cancers (IHC 3+ or IHC 2+ with FISH positive, approximately 15-20% of gastric cancers), the addition of trastuzumab (a monoclonal antibody against HER2) to chemotherapy improves median survival by 2-3 months. Ramucirumab, a VEGF receptor antagonist, is used for patients with progressive disease after first-line chemotherapy or in select cases combined with chemotherapy in first-line. Nivolumab, an immune checkpoint inhibitor (PD-1 antagonist), shows benefit in PD-L1+ tumors and is increasingly used in second-line or in combination approaches.
- FOLFOX: Fluorouracil 400 mg/m² IV + Leucovorin 200 mg/m² + Oxaliplatin 85 mg/m² every 2 weeks
- CAPOX: Capecitabine 1000 mg/m² twice daily × 14 days + Oxaliplatin 130 mg/m² day 1, every 3 weeks
- Trastuzumab 6 mg/kg IV every 3 weeks with chemotherapy for HER2+ tumors (first-line)
- Ramucirumab 8 mg/kg IV every 2 weeks with or without chemotherapy (second-line or maintenance)
- Nivolumab 240 mg IV every 2 weeks for PD-L1+ or MSI-high tumors (second or third-line)
- Fluorouracil monotherapy with or without mitomycin C (for frail patients or those declining combination therapy)
Radiation Therapy
Radiation therapy has a limited role in gastric cancer compared to other malignancies. It is not routinely recommended as adjuvant therapy after gastrectomy in most patients, as chemotherapy outcomes are superior. However, in select situations, external beam radiation may be considered: (1) after incomplete resection (R1 or R2 resection) to improve local control, (2) for palliative treatment of severe bleeding or pain from the primary tumor, and (3) to treat isolated metastases (e.g., brain metastasis).
When radiation is used, modern techniques like intensity-modulated radiation therapy (IMRT) or image-guided radiotherapy (IGRT) minimize toxicity to surrounding organs (small bowel, heart, lungs). Typical doses range from 50-54 Gy in conventional fractionation. Combination with chemotherapy (concurrent chemoradiotherapy) is often employed but requires careful patient selection to minimize toxicity.
- External beam radiation therapy (IMRT/IGRT) 45–54 Gy in 25–30 fractions to primary tumor bed and regional nodes (for incomplete resection or palliative intent)
- Stereotactic body radiation therapy (SBRT) for isolated metastases (e.g., brain, adrenal, isolated liver lesions)
- Concurrent chemotherapy with radiation (fluorouracil-based) for select locally advanced or unresectable cases
Targeted Therapy and Immunotherapy
Targeted therapies have transformed gastric cancer treatment. HER2-positive gastric cancers (15-20% of adenocarcinomas), identified by immunohistochemistry (IHC 3+) or fluorescence in situ hybridization (FISH), benefit significantly from trastuzumab, a monoclonal antibody against HER2. This agent is approved both in combination with first-line chemotherapy for advanced disease and with ramucirumab in the second-line setting.
Ramucirumab, a VEGF receptor 2 antagonist, is approved for advanced gastric cancer as second-line therapy (progression after first-line chemotherapy) and may be combined with chemotherapy in select cases. Microsatellite instability (MSI) or mismatch repair (MMR) deficiency is found in 20-30% of gastric cancers and predicts response to immune checkpoint inhibitors.
Nivolumab and pembrolizumab, PD-1 checkpoint inhibitors, show efficacy in MSI-high or PD-L1+ gastric cancers, particularly in second or later lines of therapy. These agents work by unleashing the immune system to attack cancer cells. Overall response rates are 15-20%, but responders can achieve durable remissions. Immunotherapy is increasingly incorporated into first-line regimens for selected patients with favorable biomarkers.
- Trastuzumab 6 mg/kg IV every 3 weeks (for HER2+ tumors, first-line with chemotherapy)
- Ramucirumab 8 mg/kg IV every 2 weeks (for advanced disease, second-line or with chemotherapy)
- Nivolumab 240 mg IV every 2 weeks (for MSI-high or PD-L1+ tumors, second or third-line)
- Pembrolizumab 200 mg IV every 3 weeks (for MSI-high tumors, second-line)
- Apatinib (tyrosine kinase inhibitor targeting VEGFR) 500 mg daily (second-line option, particularly in Asian populations)
Why Adjuvant Chemotherapy Matters After Surgery
Stomach cancer has a high propensity for lymph node involvement and micrometastatic disease at the time of surgery, even in patients undergoing successful resection. Studies show that 50-60% of patients with stage IB or higher disease have occult metastatic disease not detected by preoperative imaging. Without additional treatment, these patients have high relapse rates (50-70% within 2-3 years). Adjuvant chemotherapy significantly improves disease-free survival and overall survival by eliminating these microscopic disease foci.
The landmark GASTRIC trial and meta-analyses demonstrate that adjuvant fluoropyrimidine-platinum chemotherapy improves 5-year overall survival by approximately 12-15% compared to surgery alone. For stage III disease, the benefit is even more pronounced. The 6-month course of FOLFOX or CAPOX is well-tolerated in most patients who recover adequately from surgery (typically after 4-6 weeks). Early initiation of adjuvant therapy (within 6-8 weeks of surgery) is important to maximize efficacy. At VICI Healthcare, we prioritize adjuvant chemotherapy for all eligible patients and provide comprehensive supportive care to manage side effects and maintain treatment adherence.
What to Expect: A Day at VICI Healthcare for Stomach Cancer Treatment
-
8:30 AM
Patient arrives for chemotherapy session (FOLFOX or CAPOX). Registration and important signs (blood pressure, temperature, weight) recorded. Recent blood work reviewed (CBC, liver and kidney function, tumor markers if applicable).
-
9:00 AM
Oncologist review
Assessment of treatment tolerance, review of any side effects since last visit, physical examination, and evaluation for dose modifications if needed. Discussion of upcoming treatment cycle and expectations.
-
9:30 AM
IV access established (insertion of peripheral IV line or use of existing port-a-cath). Antiemetics (nausea prevention medications) started as premedication, typically dexamethasone and 5-HT3 antagonists.
-
10:00 AM
Chemotherapy infusion begins. For FOLFOX
Leucovorin and oxaliplatin infusion, then 5-FU bolus and continuous infusion pump. Patient may nap, read, or work during 4-5 hour infusion. Nurses monitor continuously for any reactions.
-
2:00 PM
Chemotherapy infusion completed. Patient discharged with portable infusion pump (if applicable) or sent home after observation. Discharged with written post-treatment instructions and emergency contact numbers.
-
2:30 PM
Nutritionist consultation available on same day or scheduled for follow-up. Discussion of dietary strategies to manage side effects (nausea, taste changes, diarrhea). Meal planning to ensure adequate protein and calorie intake during treatment.
-
3:00 PM
Psycho-social support
Optional counseling or support group discussion about managing chemotherapy side effects, emotional well-being, and addressing concerns. Information about symptom management resources provided.
-
Next appointment
Scheduled 2 weeks later for next FOLFOX cycle or every 3 weeks for CAPOX. Patients may have clinic visits between infusions for blood work and monitoring. Regular contact with care team (phone/email) available for questions or concerns.
Treatment Costs for Stomach Cancer in India
Below are estimated costs for standard gastric cancer treatments in India. Actual costs vary widely depending on hospital location (metros vs. smaller cities), specialization level, and additional supportive care. Government hospitals typically offer significantly reduced costs. Private insurance coverage varies by policy; pre-authorization is often required.
| Scenario | Treatment Combination | Govt Hospital | Private Hospital |
|---|---|---|---|
| Early-stage (Stage IA-IB) Gastrectomy alone | Subtotal or total gastrectomy with D2 lymph node dissection (uncomplicated case, 5-7 days hospitalization) | ₹80,000 – ₹150,000 | ₹350,000 – ₹700,000 |
| Adjuvant FOLFOX (6 months) | 12 cycles of fluorouracil, leucovorin, oxaliplatin (outpatient chemotherapy, blood work, supportive medications) | ₹200,000 – ₹400,000 | ₹600,000 – ₹1,200,000 |
| Neoadjuvant + Surgery + Adjuvant Chemotherapy | 3 cycles FOLFOX pre-op, gastrectomy (7-10 days), 3 cycles post-op FOLFOX (total 6 months) | ₹500,000 – ₹800,000 | ₹1,500,000 – ₹2,500,000 |
| Palliative FOLFOX for metastatic disease (ongoing until progression) | Continuous or intermittent chemotherapy, average 8-12 cycles, supportive care, hospitalization for complications as needed | ₹300,000 – ₹600,000 (per 6 months) | ₹800,000 – ₹1,600,000 (per 6 months) |
| Trastuzumab (HER2+ tumors, 12 months) | Trastuzumab with chemotherapy, weekly or every 3 weeks infusions (17 doses typically for HER2+ gastric cancer with chemotherapy) | ₹200,000 – ₹400,000 | ₹600,000 – ₹1,200,000 |
| Ramucirumab for advanced disease (second-line, 6 months) | Biweekly IV infusions, approximately 13 doses with supportive care and monitoring | ₹300,000 – ₹500,000 | ₹800,000 – ₹1,500,000 |
| Nivolumab (immunotherapy, MSI-high or PD-L1+ tumors) | Biweekly IV infusions, cost varies with treatment duration; approximately 6-12 months average | ₹400,000 – ₹800,000 | ₹1,200,000 – ₹2,400,000 |
| Comprehensive care bundle (surgery + chemotherapy + follow-up 1 year) | Complete perioperative chemotherapy (neoadjuvant + surgery + adjuvant), scans, blood work, nutritional support, psycho-social care | ₹700,000 – ₹1,200,000 | ₹2,000,000 – ₹4,000,000 |
Costs include hospitalization, surgical fees, chemotherapy drugs, blood work/imaging, and basic supportive care. Costs may increase if complications arise (neutropenia, neuropathy management, parenteral nutrition). Targeted therapies (trastuzumab, ramucirumab) and immunotherapy (nivolumab) significantly increase total cost. Government schemes (Ayushman Bharat, state-specific schemes) may cover portions in eligible populations. Insurance reimbursement varies. Costs are approximate and represent 2026 pricing in major Indian metros; prices lower in tier-2 cities.
How Modern Treatment Differs from Traditional Approaches
| Factor | Traditional Hospitalization | VICI Day-Care |
|---|---|---|
| Surgical Technique | Gastrectomy with basic dissection; often limited lymph node removal, higher risk of residual disease. | Standardized D2 lymphadenectomy (removal of regional lymph nodes) and minimal-access laparoscopic techniques where appropriate. Oncologic principles ensure complete staging and lower recurrence rates. |
| Chemotherapy Timing | Chemotherapy given only after surgery (adjuvant) if given at all; many patients receive no chemotherapy. | Perioperative approach: neoadjuvant chemotherapy before surgery (shrinks tumors, improves resectability) followed by gastrectomy and adjuvant chemotherapy. Improves survival by 10-15%. |
| Chemotherapy Regimens | Monotherapy with single agents or weak combinations; limited evidence of benefit. | Doublet and triplet combinations (FOLFOX, CAPOX) based on clinical trials. Evidence-based regimens improve survival and are considered standard of care worldwide. |
| Targeted Therapy | Not used; chemotherapy only, regardless of tumor characteristics. | Molecular testing for HER2, MSI/MMR status, and PD-L1. HER2+ tumors treated with trastuzumab; MSI-high tumors may receive immunotherapy. Personalized medicine approach. |
| Side Effect Management | Minimal proactive management; patients suffer through nausea, neuropathy, and other effects. | Comprehensive supportive care: antiemetics, anti-diarrheal agents, nutritional support, prophylaxis for infections. Quality of life prioritized alongside cure. |
| Nutrition and Rehabilitation | Post-operative nutrition haphazard; patients often suffer malnutrition and poor recovery. | Structured nutritional assessment and intervention from day of surgery. Dietitian-designed meal plans, oral nutritional supplements, and parenteral nutrition if needed. Early mobilization and rehabilitation protocols. |
| Follow-up and Surveillance | Limited follow-up; early recurrence often detected only when symptomatic (stage IV). | Regular surveillance with imaging and tumor markers every 3-6 months for first 2-3 years. Earlier detection of recurrence enables earlier intervention, potentially improving outcomes. |
| Psycho-social Support | Primarily medical focus; emotional and psychological impacts minimized or ignored. | Integrated psycho-social care: counseling, support groups, family education, financial guidance, and resources for coping strategies. Recognition that psychological well-being is integral to cancer care. |
Weighing the Benefits and Challenges of Gastric Cancer Treatment
Curative potential with surgery: Complete surgical resection offers the only chance for cure, with 5-year survival rates of 50-70% in early-stage disease. This major advantage justifies the recovery period and temporary lifestyle changes.
Improved survival with adjuvant chemotherapy: Evidence-based chemotherapy improves survival by 12-15% and extends disease-free intervals, helping many patients live longer and more productive lives.
Targeted therapy options for HER2+ tumors: Trastuzumab significantly improves outcomes in HER2-positive gastric cancers, offering a personalized approach that improves efficacy beyond chemotherapy alone.
H. pylori eradication prevents recurrence: Treating H. pylori infection reduces long-term cancer risk and is simple, non-toxic, and inexpensive. This is particularly relevant for Indian populations.
Managed side effects improve quality of life: Modern supportive care protocols minimize nausea, neuropathy, and other treatment-related toxicities, allowing patients to maintain work and family roles during therapy.
Surgical morbidity and recovery period: Gastrectomy involves major surgery with 6-12 weeks recovery. Permanent nutritional changes (post-gastrectomy syndrome, B12/iron deficiency) require lifelong supplementation and dietary modifications.
Chemotherapy side effects: FOLFOX causes peripheral neuropathy (nerve damage in feet/hands), hand-foot syndrome, diarrhea, and hematologic toxicities. Some side effects are irreversible or take months to resolve.
Limited efficacy in advanced disease: Metastatic gastric cancer has poor prognosis despite modern therapy; median survival is 8-14 months. For many stage IV patients, cure is not realistic, and therapy aims for life extension and symptom relief.
Nutritional challenges post-gastrectomy: Dumping syndrome, decreased appetite, altered taste, and difficulty eating meat/fatty foods affect 30-50% of patients long-term. Requires dietary vigilance and supplements.
Cost barriers in India: Complete perioperative therapy costs ₹2-4 million in private sector, limiting access. Even government sector costs (₹700,000+) exceed affordability for many families. Insurance coverage varies widely.
Limited screening programs: Unlike early-detected cancers (stage I-II with 60-75% survival), most Indian patients present with stage III-IV disease due to late detection. Public awareness and screening capacity remain inadequate.
Chemotherapy-induced cognitive impairment: Some patients experience ‘chemo brain’—difficulty concentrating, memory problems—which may persist after treatment. Impact on work and daily function varies.
Managing Side Effects of Gastric Cancer Treatment
-
FOLFOX Chemotherapy
- Side effects
- Nausea and vomiting (40-60% of patients); diarrhea or constipation; peripheral neuropathy (numbness in hands/feet, 15-20% grade 3+); hand-foot syndrome; decreased blood counts (anemia, low white…
- How we manage it
- Antiemetics (5-HT3 antagonists like ondansetron, dexamethasone) given routinely before infusion. Anti-diarrheal agents (loperamide) and stool softeners prescribed. Neuropathy managed with dose reduction of oxaliplatin if…
-
CAPOX Chemotherapy
- Side effects
- Hand-foot syndrome (palmoplantar erythrodysesthesia, 30-50% of patients); diarrhea (variable severity); nausea and vomiting; bone marrow suppression; fatigue; less peripheral neuropathy than FOLFOX.
- How we manage it
- Hand-foot syndrome managed with cooling measures (ice packs, foot soaks), topical emollients, and dose reduction if severe. Anti-diarrheal and anti-nausea medications. Monitoring of blood counts…
-
Post-Gastrectomy Surgery
- Side effects
- Dumping syndrome (flushing, palpitations, diarrhea 15-30 minutes after eating, 20-30% of patients); early satiety (feeling full quickly); nutritional deficiencies (B12, iron, calcium, vitamin D); post-operative…
- How we manage it
- Dietary modifications: small frequent meals, avoiding simple sugars and high glycemic index foods, eating protein with each meal. Octreotide (somatostatin analog) for severe dumping syndrome….
-
Trastuzumab (HER2-targeted therapy)
- Side effects
- Cardiomyopathy and heart failure risk (1-3% of patients); infusion reactions (fever, chills, dyspnea, 2-5%); diarrhea; nausea; mild anemia.
- How we manage it
- Baseline echocardiogram and regular cardiac monitoring (every 3 months during therapy). LVEF (left ventricular ejection fraction) monitored; trastuzumab held if LVEF drops >10% or to…
-
Ramucirumab (VEGFR2-targeted therapy)
- Side effects
- Hypertension (30-40% of patients); bleeding risk (epistaxis, GI bleeding in 2-3%); proteinuria; thrombosis risk; infusion reactions; diarrhea.
- How we manage it
- Blood pressure monitoring at every visit; antihypertensive therapy started if needed. Avoidance in patients with recent GI bleeding. Regular urinalysis for protein. Thrombosis prophylaxis considered…
-
Nivolumab (PD-1 Immunotherapy)
- Side effects
- Immune-related adverse events (irAEs): pneumonitis (inflammation of lungs, 1-3%), colitis/diarrhea (2-4%), hepatitis (1-2%), endocrinopathy (thyroid, adrenal dysfunction); fatigue; rash.
- How we manage it
- Regular monitoring of liver and thyroid function, chest imaging. IRaEs managed with corticosteroids (methylprednisolone, prednisone) for moderate-severe events; holding nivolumab until resolution. Specialist consultation (pulmonology,…
-
Radiation Therapy (if used)
- Side effects
- Acute: nausea, vomiting, diarrhea, abdominal discomfort. Chronic: small bowel fibrosis and obstruction (2-5%), gastric ulceration, perforation risk (rare).
- How we manage it
- Antiemetics and anti-diarrheal medications during active therapy. High-protein, low-fat diet. Gastroenterology follow-up for chronic effects. Surgical consultation if small bowel obstruction occurs. Nutritional support ongoing.
Read the full side effects guide for Stomach Cancer →
Frequently Asked Questions
What is my chance of surviving stomach cancer?
Survival depends strongly on stage at diagnosis. Early-stage (IA-IB) cancers have 5-year survival rates of 60-75% with surgery and adjuvant chemotherapy. Stage II has 40-50% survival. Stage III drops to 15-35%. Stage IV (metastatic) has only 5-10% 5-year survival, though median survival with modern chemotherapy is 8-14 months. In India, earlier detection in high-risk groups (H. pylori-positive, family history) and broader access to multimodal therapy could significantly improve these outcomes.
If I have a family history of stomach cancer, should I be screened?
Yes, especially if a first-degree relative (parent, sibling) had gastric cancer before age 60 or if you have a known hereditary diffuse gastric cancer (CDH1 mutation) in the family. Recommended screening approaches include upper endoscopy every 2-3 years starting at age 40 or 10 years before your relative’s diagnosis. H. pylori testing and eradication is recommended for all infected family members. Genetic counseling is advised if hereditary syndrome is suspected.
What is the significance of H. pylori in stomach cancer risk?
H. pylori is classified as a Group 1 carcinogen (definite human carcinogen). In India, 60-70% of the population is infected. H. pylori infection increases gastric cancer risk by 5-10 fold, primarily through chronic inflammation leading to atrophic gastritis and intestinal metaplasia. Eradication therapy (triple or quadruple drug combinations for 10-14 days) reduces cancer risk by 30-50%. All infected individuals, especially those with symptoms or family history, should be treated.
Is stomach cancer curable?
Early-stage stomach cancer (stages IA-IB) is potentially curable with complete surgical resection, with cure rates of 60-75% at 5 years. Stage II is less curable (40-50% 5-year survival). Stage III can be cured in 15-35% of patients with aggressive multimodal therapy. Stage IV (metastatic) is generally not curable, though some patients may achieve long-term survival with modern chemotherapy. Cure is most likely when cancer is detected early, which emphasizes the importance of screening in high-risk groups.
Do I need chemotherapy after surgery?
Adjuvant (post-operative) chemotherapy is recommended for all patients with stage IB disease or higher. Clinical trials demonstrate that 6 months of FOLFOX or CAPOX chemotherapy improves overall survival by 12-15% compared to surgery alone. For stage III disease, the benefit is even more pronounced. Standard of care at major cancer centers worldwide includes adjuvant chemotherapy for stage IB+. Benefits outweigh side effects for eligible patients.
What does HER2-positive mean and why does it matter?
HER2 (human epidermal growth factor receptor 2) is a protein on the surface of some cancer cells. About 15-20% of gastric adenocarcinomas are HER2-positive. HER2-positive gastric cancers tend to be more aggressive but respond very well to targeted therapy with trastuzumab (Herceptin), a monoclonal antibody against HER2. Adding trastuzumab to first-line chemotherapy improves median survival by 2-3 months. Therefore, HER2 testing is essential at diagnosis, and HER2-positive patients should receive trastuzumab as part of their treatment.
What is MSI (microsatellite instability) and why is it tested?
Microsatellite instability (MSI) is a biomarker indicating defects in DNA repair genes (mismatch repair deficiency, MMR-d). About 20-30% of gastric cancers are MSI-high. MSI-high tumors respond exceptionally well to immune checkpoint inhibitors like nivolumab and pembrolizumab. These immunotherapies can produce response rates of 40-50% in MSI-high tumors compared to 10-15% in MSI-stable tumors. Testing for MSI (by DNA sequencing or immunohistochemistry) is now standard and guides selection of immunotherapy, especially in advanced disease.
Are there newer drugs beyond FOLFOX for stomach cancer?
Yes. Beyond standard chemotherapy (FOLFOX, CAPOX), newer options include: Trastuzumab (for HER2+ tumors); Ramucirumab (a VEGF antagonist for advanced disease); Nivolumab and Pembrolizumab (immune checkpoint inhibitors for MSI-high or PD-L1+ tumors); and Apatinib (a tyrosine kinase inhibitor used primarily in Asian populations). These are typically added to chemotherapy in first-line or used in second-line progression. Availability varies by region and institutional access in India.
How long is the recovery period after gastrectomy?
Most patients stay in hospital for 5-7 days post-operatively if uncomplicated. Initial wound healing and pain management take 2-3 weeks. Return to normal diet is gradual, taking 4-6 weeks. Most patients can return to light desk work in 4-6 weeks and full activities in 8-12 weeks. Full nutritional recovery and adaptation to the new stomach capacity takes 3-6 months. Permanent changes include need for frequent small meals, avoidance of very hot/cold foods, and lifelong supplementation (B12, iron, calcium).
What is dumping syndrome and how is it managed?
Dumping syndrome occurs in 20-30% of post-gastrectomy patients, particularly when eating simple sugars or large meals. Symptoms include sudden flushing, palpitations, diarrhea, and weakness occurring 15-30 minutes after eating. Management includes dietary changes: small frequent meals, avoiding simple sugars and refined carbohydrates, eating protein with each meal, and limiting liquids during meals. For severe cases, octreotide (a somatostatin analog) is highly effective. Most patients adapt over 6-12 months and symptoms improve over time.
Will I need lifelong vitamin supplementation after gastrectomy?
Yes, vitamin B12 supplementation is lifelong and mandatory after total gastrectomy or extensive partial gastrectomy, since the stomach produces intrinsic factor needed for B12 absorption. B12 can be given as intramuscular injections (1000 mcg monthly or 2-3 monthly) or high-dose oral supplements (1000-2000 mcg daily). Iron supplementation is also common (ferrous sulfate 325 mg daily), and calcium + vitamin D supplementation is recommended to maintain bone density. Regular monitoring of these levels is essential.
What is the difference between curative and palliative treatment?
Curative treatment aims to eliminate cancer with the goal of achieving long-term survival and potential cure. This includes multimodal therapy (surgery, chemotherapy, sometimes radiation) appropriate for early-stage and locally advanced cancers. Palliative treatment aims to extend survival, relieve symptoms, and maintain quality of life when cure is not possible (typically in metastatic disease). Palliative chemotherapy may extend median survival from 3-4 months (with supportive care alone) to 8-14 months. The distinction is important for setting expectations and planning care goals.
Can immunotherapy cure my stomach cancer?
Immunotherapy (nivolumab, pembrolizumab) can produce durable complete responses in MSI-high or PD-L1+ gastric cancers, potentially leading to cure in some patients. However, response rates are 15-30%, meaning most patients derive limited benefit. Immunotherapy is typically used as second-line treatment or in combination with chemotherapy in first-line for advanced disease. For early-stage cancers, surgery and chemotherapy remain the primary curative approaches. Immunotherapy represents an important option but should not be viewed as a replacement for surgery and chemotherapy in curable disease.
What happens if my cancer comes back after treatment?
Recurrence may be local (at the surgical site), in lymph nodes, or distant (metastatic to liver, lungs, peritoneum). Treatment depends on the location and timing of recurrence and prior therapies. Local or lymph node recurrence may occasionally be amenable to surgery or radiation. Distant metastatic recurrence typically requires palliative chemotherapy, targeted therapy, or immunotherapy based on tumor characteristics and prior treatment. Second-line and third-line chemotherapy regimens (irinotecan-based, taxane-based) are options. Median survival after recurrence is 6-12 months with modern therapy, though this varies widely.
Is there a preventive role for endoscopy in high-risk populations in India?
Screening endoscopy in high-risk populations (H. pylori-infected, family history, atrophic gastritis, intestinal metaplasia) is recommended but not yet widely implemented in India due to cost and capacity constraints. In developed countries, Japan and South Korea have successful population-based screening programs starting at age 40, resulting in earlier detection and better survival. In India, opportunistic screening (endoscopy when symptoms arise) and H. pylori testing and eradication in at-risk groups remain the practical approach. Expansion of screening capacity in high-incidence regions (NE India, Kashmir) could substantially improve outcomes.
Medically reviewed by Oncology Team, VICI Healthcare
Last reviewed: 2026-04 | NMC Registration: [Pending]
